1 / 21

Dr. Johannes Michiel Luteijn Prof. Joan Morris BINOCAR Scientific Meeting

EUROCAT Post-marketing surveillance for congenital anomalies. Thanks to: Lolkje de Jong-van den Berg Helen Dolk Ester Garne Joanne Given Maria Loane. Dr. Johannes Michiel Luteijn Prof. Joan Morris BINOCAR Scientific Meeting Swansea, October 7 th , 2014. Drug use in pregnancy.

velma-slater
Download Presentation

Dr. Johannes Michiel Luteijn Prof. Joan Morris BINOCAR Scientific Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. EUROCAT Post-marketing surveillance for congenital anomalies Thanks to: Lolkje de Jong-van den Berg Helen Dolk Ester Garne Joanne Given Maria Loane Dr. Johannes Michiel Luteijn Prof. Joan Morris BINOCAR Scientific Meeting Swansea, October 7th, 2014

  2. Drug use in pregnancy Two studies estimated 57-79% of pregnant women in Northern Europe are exposed to prescription drugs during pregnancy.1,2 Little is known about the safety of drugs in pregnancy, partly due to pregnant women not being involved in pre-marketing studies. 1 Bakker, M. K., Jentink, J., Vroom, F., Van Den Berg, P. B., De Walle, H. E., & De Jong-Van Den Berg, L. T. (2006). Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the netherlands. BJOG : An International Journal of Obstetrics and Gynaecology, 113(5), 559-568 2 Engeland, A., Bramness, J. G., Daltveit, A. K., Ronning, M., Skurtveit, S., & Furu, K. (2008). Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in norway 2004-2006. British Journal of Clinical Pharmacology, 65(5), 653-660

  3. EUROmediCAT signal detection Aim: To develop a method of signal detection to be used as a routine analysis tool.

  4. Dataset 15 EUROCAT registries in EUROmediCAT Births from 1995-2011 14,950 registrations of congenital anomaly with at least a single exposure to a drug (ATC-code 5-digit+) Folic acid, minerals and vitamins not included as exposures Exclusions Anomalies with 1-4 digit ATC-code exposures only (n=1,288) Anomalies with no clear 1st trimester exposure (n=13,377) Infants with a chromosomal anomaly

  5. Dataset Drug exposure 5- and 7-digit ATC codes (n = 272, n = 505) Exposure collected mainly prospective to birth by healthcare professionals. Cases EUROCAT coding committee identified 59 subgroups of non-chromosomal congenital anomaly Potential drug-congenital anomaly signals must have at least 3 exposed cases 3 Teratogenic mechanisms of medical drugs. Van Gelder MM, van Rooij IA, Miller RK, Zielhuis GA, de Jong-van den Berg LTW, Roeleveld N. Hum Reprod. Update. 2010 Jul-Aug;16(4):378-94

  6. Analysis of drug-CA combinations Analysis by Fishers’ exact test A total of 59 congenital anomalies x 836 drug-codes. 49,324 analyses performed. 19,529 5-digit ATC-code analyses 29,795 7-digit ATC-code analyses

  7. Fisher’s exact results for 7-digit ATC – anomaly combinations P-value 0.05 Observed Odds Ratio

  8. Multiple testing issues P Values Given there is no association - P = probability observed or more extreme result would occur P = 0.05 means that 5% of Fisher’s exact tests where there is no association will be “statistically significant” Ie 5% of 5,000 tests are likely to be false positives False Discovery Rate: Proportion of significant results that are expected to be false positives FDR of 5% means 5% of the “significant” results are likely to be false positives Ie 5% of significant results are likely to be false positives

  9. False Discovery Rate Distribution of test statistics if there are no associations Density B Possible test results (Z-score)

  10. False Discovery Rate FDR = Distribution of test statistics if there are no associations Density Observed distribution of test statistics B A Possible test results (Z-score)

  11. False Discovery Rate FDR = 5% P-value 0.05 0.05 Observed Odds Ratio

  12. False Discovery Rate May exclude true associations FDR = 5% P-value 0.05 0.05 Observed Odds Ratio

  13. False Discovery Rate May exclude true associations FDR = 5% P-value FDR = 50% 0.05 Observed Odds Ratio

  14. False Discovery Rate May exclude true associations FDR = 5% P-value FDR = 50% May include too many false associations 0.05 Observed Odds Ratio

  15. Flowchart of analyses 49,324 drug-CA combinations 19,529 5-digit drug combinations (including aggregate drug groups) 29,795 7-digit drug combinations Multiple testing procedure (649 p-value < 0.05) Multiple testing procedure (886 p-value < 0.05) 31 potential signals at (FDR = 0.5 ; p < 0.0005) 97potential signals at (FDR= 0.5 ; p < 0.003) 128potential signals

  16. Preliminary Results – Association tree Example – Spina bifida and N03AG01 (valproic acid) Cases not yet verified by registry

  17. Flowchart of analyses Exclusions 49,324 drug-CA combinations 47,789 FDR > 0.5 128potential signals 13 Less than 3 exposed cases 115 potential signals 20 5-digit ATC code of 7-digit ATC associated with the same CA 6 Aggregate CA of a more specific CA associated with the same exposure 12Protective associations 77 Independent signals Subject to detailed follow-up

  18. Validation of methodology Spina bifida and valproic acid † OR 7.25 (4.61-11.02) 28 Exposed cases Congenital heart defects and human insulin † OR 2.46 (1.81-3.35) 102 Exposed cases † Cases not yet verified by registry

  19. Future work The WHO-Uppsala Monitoring Centre receives reports of adverse drug reactions from all over the world. 66,000 reports of CA-related adverse drug reactions since 2000 70% American/Canadian Valuable independent dataset for testing signals

More Related